More than 1,400 patients were involved in trials, with some participants with advanced bowel cancer who had already had chemotherapy prolonged life by two years. Scientists think the drug could be used across a range of different cancers.
A report in the Journal of Clinical Oncology said Aflibercept had a ‘statistically significant survival benefit’ compared to conventional drug regimes treating bowel cancer that had spread after initial treatment. pti